A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.

Asao, Tetsuhiko; Watanabe, Satoshi; Tanaka, Takahiro; Morita, Satoshi; Kobayashi, Kunihiko

Asao, Tetsuhiko; Watanabe, Satoshi; Tanaka, Takahiro; Morita, Satoshi; Kobayashi, Kunihiko.

Afiliação

Asao T; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Watanabe S; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachidori, Chuouku, Niigata, 951-8510, Japan. satoshi7@med.niigata-u.ac.jp.
Tanaka T; Clinical and Translational Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kobayashi K; Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan.

BMC Cancer ; 22(1): 1135, 2022 Nov 04.

Article em En | MEDLINE | ID: mdl-36333680

Assuntos

Neoplasias Pulmonares; Carcinoma de Pequenas Células do Pulmão; Humanos; Carboplatina; Etoposídeo; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico; Ensaios Clínicos Fase II como Assunto; Estudos Multicêntricos como Assunto

Palavras-chave

Anti-PD-L1; Durvalumab; Immune checkpoint inhibitor; Poor performance status; Small-cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Pequenas Células do Pulmão / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google